Abstract: A polymeric construct is disclosed. The construct comprises a biodegradable ABA block copolymer having a selected medicament associated therewith. The medicament thus present is provided in a slow release form.

Abstract: This invention relates to medicinal aerosol and more formulation and more particularly, to a medicinal aerosol formulation containing rosiglitazone maleate and a fluid carrier.

Abstract: A medicinal formulation is disclosed comprising pioglitazone or a derivative thereof. The formulation additionally comprises a fluid carrier and a stabilizer.

Abstract: A polymeric construct is disclosed. The construct comprises a polymer selected from silica gel, fumed silica gel, silicic acid, disilicic acid, trisilicic acid, metasilicic acid, and orthosilicic acid in their free or salt forms; silicon dioxide in either of its amporphous, crystalline, or precipitated forms such as Purified Siliceous Earth; diatomacous earth; Fuller's earth, Kieselhurh, Celite; talc; attapulgite; micas; montmorilonite, kaolin, aluminum oxide (Hydrargilite), bentonite, pumice; silanes and siloxanes and any mixture of the foregoing having a selected medicament associated therewith. The medicament thus present is provided in a slow release form.

Abstract: A method of treating in a human or animal a condition capable of treatment by oral or nasal inhalation has been found. The method comprises administering a medicinal aerosol formulation comprising a selected medicament under conditions where the amount of the selected drug delivered to the site of action, e.g. the lungs, is maximized.

Abstract: A medicinal formulation is disclosed. The formulation comprises (a) a protein or peptide medicament; (b) a fluid carrier for containing said medicament; and a stabilizer selected from an amino acid, a derivative thereof or a mixture of the foregoing.

Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a troglitazone medicament and a fluid carrier.

Abstract: A modulated release aerosol formulation is disclosed. The formulation comprises a polysaccharide polymer having a selected medicament associated therewith, a fluid carrier for carrying and delivering the construct and a stabilizer.

Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing pioglitazone medicament and a fluid carrier.

Abstract: A modulated release aerosol formulation is disclosed. The formulation comprises a polymer, e.g. silica gel, fumed silica gel, having a selected medicament associated therewith, a fluid carrier for carrying and delivering the construct and a stabilizer.

Abstract: This invention relates to a medicinal aerosol formulation and, more particularly, to a medicinal aerosol formulation an insulin combination and a fluid carrier.

Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a &bgr;-cell hypoglycemic agent and a fluid carrier.

Abstract: A modulated release aerosol formulation is disclosed. The formulation comprises a polymer, e.g. Silica gel, fumed silica gel, having a selected medicament associated therewith, and a fluid carrier for carrying and delivering the construct.

Abstract: A modulated release aerosol formulation is disclosed. The formulation comprises a polymer, e.g. Silica gel, fumed silica gel, having a selected medicament associated therewith, and a fluid carrier for carrying and delivering the construct.

Abstract: A non-aqueous medicament aerosol formulation comprising troglitazone, or a derivative thereof, a fluid carrier, and an amino acid stabilizer. The aerosol formulation may also include drug combination formulations comprising troglitazone and a second anti-diabetic medicament.

Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, a propellant and a stabilizing agent selected from an amino acid, an amino acid derivative and a mixture of the foregoing.

Abstract: This invention relates to a controlled release combination drug product comprising troglitazone, e.g. its hydrochloride, and a biguamide, e.g. metformin. In particular, the product comprises a core of metformin, at least a portion thereof has a layer or coat thereon of troglitazone.

Abstract: This invention relates to a medical aerosol formulation and more particularly, to a medicinal aerosol formulation containing a rosiglitazone maleate and a fluid carrier.

Abstract: This invention relates to a modulating formulation comprising pioglitazone hydrochloride and a biguamide, e.g. metformin. In particular, the product comprises a core of the biguamide, e.g. metformin, at least a portion thereof has a layer or coat thereon of pioglitazone.

Abstract: This invention relates to a combination drug product comprising troglitazone, e.g. its hydrochloride, and a biguamide, e.g. metformin. In particular, the product comprises a core of metformin, at least a portion thereof has a layer or coat thereon of troglitazone.